title: Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers.
abstract: While there is limited prospective data on the incidence of venous thromboembolism (VTE) in the burn population, there are no prospective studies on the efficacy and safety of VTE prophylaxis in these patients. Despite lack of such data, we hypothesized that most burn centers practice some form of prophylaxis. Eighty-four US burn centers were contacted regarding their modality of VTE prophylaxis, if any. Of the 84 US burn centers, 71 were enrolled in this survey. 76.1% centers reported routine VTE prophylaxis. Modalities included sequential compression device (SCD) (33), subcutaneous heparin (31), enoxaparin (13), dalteparin (3), and intravenous heparin infusion (1). Twenty-one reported combined modalities of SCD and subcutaneous heparin (19), SCD and enoxaparin (1), or SCD and dalteparin (1). Survey results underscore the need to definitively establish risk factors for VTE in the burn population and to prospectively define an evidence-based standard of care in prophylaxis for those patients.
authors.affiliation: Division of Plastic Surgery, University of Kentucky College of Medicine, Lexington, KY 40536, USA. dr.rob@uky.edu
authors.forename: Robert E H
authors.initials: RE
authors.lastname: Ferguson
authors.forename: Agatha
authors.initials: A
authors.lastname: Critchfield
authors.forename: Aimee
authors.initials: A
authors.lastname: Leclaire
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ajkay
authors.forename: Henry C
authors.initials: HC
authors.lastname: Vasconez
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002053:Burn Units; D002056:Burns / Q000097:blood* / Q000188:drug therapy; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D006306:Health Surveys; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control*; D014481:United States; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D006493:Heparin; D017985:Dalteparin